603883.SH上海证券交易所 · 主板 Main
Lbx Pharmacy Chain 老百姓
Pharmaceutical Distribution 医药商业
¥12.95+¥0.05 · +0.39%
Open 开盘
¥12.90
High 最高
¥13.05
Low 最低
¥12.83
Prev Close 昨收
¥12.90
Volume 成交量
909.5万股
Turnover 成交额
¥1.18亿
Mkt Cap 总市值
¥98亿
P/E 市盈率
22.8×
Recent Activity 近期动态All Filings 全部公告 →
31 significant filings since 29 May 2026: 1 on share pledge, 20 on equity incentive and 5 on buyback, and 3 other kinds. The latest, on 15 Sep 2026: 关于以集中竞价方式首次回购股份的进展公告.
自 29 May 2026 起有 31 份重大公告：share pledge 1 份、equity incentive 20 份、buyback 5 份，另有 3 类。最新一份（15 Sep 2026）：关于以集中竞价方式首次回购股份的进展公告。
Price History 价格走势
5 sessions 个交易日, 18 Sep to 24 Sep 2026 · Live one-minute prices · High 最高 ¥13.04 · Low 最低 ¥12.58 · +0.39% on the previous close of ¥12.9012.6012.7012.8012.9013.00
18 Sep21 Sep22 Sep23 Sep24 Sep
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Pharmaceutical Distribution 医药商业 · 30 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥98亿 | ¥59亿 | 9th highest of 30 · 30 家中第 9 高 | |
| Trailing P/E 市盈率 | 22.8x | 22.9x | 12th lowest of 25 · 25 家中第 12 低 | |
| P/B 市净率 | 1.4x | 1.2x | 14th highest of 30 · 30 家中第 14 高 | |
| Revenue Growth 营收增速 | 2.1% | 0.3% | 12th highest of 30 · 30 家中第 12 高 | |
| Profit Growth 净利增速 | 12.3% | -7.2% | 8th highest of 30 · 30 家中第 8 高 | |
| Gross Margin 毛利率 | 32.5% | 11.2% | 7th highest of 30 · 30 家中第 7 高 | |
| Net Margin 净利率 | 4.8% | 1.6% | 7th highest of 30 · 30 家中第 7 高 | |
| Return on Equity 净资产收益率 | 6.6% | 3.0% | 5th highest of 30 · 30 家中第 5 高 | |
| Debt to Assets 资产负债率 | 60.6% | 61.0% | 15th lowest of 30 · 30 家中第 15 低 | |
| Grade Score 评级得分 | 67 | 47 | 5th highest of 30 · 30 家中第 5 高 |
Statement figures are for the period to 30 Jun 2026, filed by 30 of 30 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，30 家同业中 30 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Shanghai Pharma 上海医药 | ¥594亿 | 12.4x | 0.8x | 4.2% | 2.9% | 4.5% | C |
| Yifeng Pharmacy 益丰药房 | ¥268亿 | 15.2x | 2.3x | 3.5% | 8.8% | 8.0% | B |
| Jointown 九州通 | ¥244亿 | 12.1x | 0.9x | 7.6% | 1.4% | 4.2% | D |
| DaShenLin Pharmaceutical Group 大参林 | ¥200亿 | 14.7x | 2.6x | 3.5% | 7.2% | 11.6% | B |
| China National Medicines 国药股份 | ¥194亿 | 10.1x | 1.0x | 4.3% | 3.3% | 4.7% | C |
| Qingdao Baheal Medical 百洋医药 | ¥133亿 | 24.7x | 5.8x | -5.1% | 7.9% | 9.3% | C |
| China Meheco 中国医药 | ¥133亿 | 30.9x | 1.1x | -0.7% | 1.8% | 2.1% | D |
| China National Accord Medicines 国药一致 | ¥119亿 | 11.1x | 0.6x | -1.4% | 1.8% | 3.2% | D |
| Lbx Pharmacy Chain 老百姓 | ¥98亿 | 22.8x | 1.4x | 2.1% | 4.8% | 6.6% | C |
| C.Q. Pharmaceutical Holding 重药控股 | ¥89亿 | 24.8x | 0.8x | -2.6% | 0.8% | 2.2% | E |
| Shanghai C&D Innostic Medical Technology 建发致新 | ¥83亿 | 29.7x | 3.8x | 1.8% | 1.9% | 6.8% | D |
| Nanjing Pharmaceutical Group 南京医药 | ¥64亿 | 10.2x | 0.9x | -0.5% | 1.4% | 4.0% | D |
| Yixintang Pharmaceutical Group 一心堂 | ¥62亿 | 22.9x | 0.8x | -5.0% | 3.1% | 3.5% | C |
| Guangxi Liuyao Group 柳药集团 | ¥60亿 | 9.3x | 0.8x | 2.2% | 3.5% | 4.6% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。